Meningitis Vaccine (C0921003)

Immunogenicity and safety study of 1 and 2 doses of GSK Biologicals’ meningococcal vaccine GSK134612 in toddlers, persistence up to 5 years after vaccination and co-administration with Pfizer’s pneumococcal vaccine Prevenar 13™.

Register Today!

Trial Information

Start DateOctober 2013
End DateJanuary 2019
Trial Duration6 years
Number of Visits7
Lead CRCJessica Richer

For additional information
on this trial contact: